Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana, Nurqisthi Iqlima Adiputri, Lily Indriani Octovia, Sekar Ayu Paramita, Rano Kurnia Sinuraya · 2026
Read Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review by Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana, Nurqisthi Iqlima Adiputri, Lily Indriani Octovia, Sekar Ayu Paramita, Rano Kurnia Sinuraya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13623077.txt.
Description
Puspitasari and a large team (2026) scoped recent studies of anti-obesity medications. Obesity drives illness and early death worldwide, and drugs are now a major part of treatment. Searching two databases in May 2025, the team gathered 42 articles covering 41 studies from the last five years, spanning several drug families.
The gut-hormone drugs known as GLP-1 agonists gave steady, large losses, with semaglutide at roughly 10 to 16 percent of body weight. The dual-action drug tirzepatide did better still, at about 15 to 21 percent over 20 to 70 weeks. Newer multi-receptor drugs also looked promising. Older non-hormone drugs, microbe-based therapies, and supplements gave smaller or patchier results. Stomach and gut side effects were the commonest complaint across the hormone-based drugs. The authors call for head-to-head trials and long-term real-world data on the newer agents.
Catalog record
| CREATOR | Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana, Nurqisthi Iqlima Adiputri, Lily Indriani Octovia, Sekar Ayu Paramita, Rano Kurnia Sinuraya |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |